.webp)
Your co-pilot for clinical monitoring
Medable’s CRA Agent is an AI-driven solution that automates and optimizes clinical trial monitoring by proactively identifying and prioritizing site risks, generating comprehensive pre-visit summaries, and providing actionable recommendations to enhance trial oversight and compliance.
We estimate that CRA agents can take on up to 90% of the tactical and administrative work the CRA handles on a daily basis — from sending site-specific emails and reminders to tracking responses and updating systems. That means we can focus our time on the strategic decisions that move trials forward, while standardizing and streamlining the tasks that used to consume most of our day.
Connected monitoring across systems
Perceive signals across the entire clinical data ecosystem by unifying CTMS, RTSM, EDC, labs, consent, and safety into one view. Turn manual checks into automated insights, instantly highlighting which sites are on track and where intervention is needed, saving valuable time, system-hopping, and manual data compilation.
Human-in-the-loop oversight
Easily identify risks and recommendations for best-next actions tied to your protocol, consent, and regulatory requirements. Stay assured with a transparent reasoning trail thatshows why each step is advised, enabling CRAs to collaborate confidently with sites, improve decision-making, enhance their compliance, all while freeing CRAs to focus on engagement and site-specific challenges.
Automated administrative tasks
Take advantage of automated routine tasks like drafting queries, sending emails, and updating CTMS/eTMF — always with human CRA oversight. Close the loop between planning and execution with real-time tracking that reduces administrative burden, ensures data consistency, and accelerates trial progress.
The latest from Knowledge Centers
Sponsors talk AI: Sanofi's take on the evolving role of AI in clinical trials
Artificial intelligence continues to move from experimentation to execution across the life sciences industry. On a recent episode of the AI in Business podcast, Matthew Peruhakal, Global Head of Data Architecture, Utilization, and AI Engineering at Sanofi, offered a deep look at how the pharmaceutical giant is integrating AI to transform clinical trials. From intelligent data workflows to proactive risk detection and regulatory alignment, Peruhakal described an organization reshaping its research and development operations around a new digital core.
His message was clear: AI cannot remain a side project. To make a meaningful impact, it must be embedded as a strategic capability that connects people, systems, and data across the enterprise.
Sponsors talk AI: Novartis’ take on the evolving role of AI in clinical trials
Artificial intelligence is shifting from promise to practice in biopharma, and few domains feel the impact more than clinical development. In a recent conversation on the AI in Business podcast, Zhong Lu, director of data science and AI at Novartis, outlined how AI is evolving the clinical trials process end to end. His perspective centered on building internal platforms that unite structured and unstructured data, deploying document intelligence to remove process friction, and using responsible generative AI to support scientific decision making without compromising compliance. While the regulatory bar remains high and patient trust is paramount, Novartis’s approach shows how targeted applications of AI can streamline data operations, strengthen regulatory readiness, and make both traditional and decentralized trials faster and more resilient.
Driving a high-adherence LTFU trial without an EDC
Learn how Medable powered a decade-long, global long-term follow-up (LTFU) obesity study, achieving an impressive 97% patient retention rate without using a traditional EDC system all while delivering a compliant, scalable, and cost-efficient solution.
Eliminate clinical trial white space with the right AI strategy
It has become clear that our industry has reachedthe limits of human-only clinical development. As clinical trials have become increasingly complex, the endeavors that people alone can perform are no longer sufficient to generate the momentum needed to address the growing burden of human disease. This has led to longer drug development timelines and significant delays for patients. One large are of lost time is “white space,” definied simply as unproductive time caused by manual, sequential processes and fragmented data systems. Thankfully, a solution lies in agentic AI and its abilities to perform series of tasks.